AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04824612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Hexacetonide
Description: intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
Study NCT04824612 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
Study NCT04824612 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LED
Description: A blue LED without power and biologic effect.
Study NCT06641245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: folic acid (0.6 mg)
Study NCT06641245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF (5-methyltetrahydrofolate)
Description: 0.625 mg/d (6S)-5-MTHF
Study NCT05705908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Foot Bath 1
Description: * Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).
Study NCT05705908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Foot Bath 2
Description: * Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water
Study NCT06359483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Frequency Manipulation
Description: The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
Study NCT05248217 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: healthcare workers
Description: healthcare
Study NCT04838366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Description: study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
Study NCT05381025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kava (Piper methysticum) extract
Description: Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
Study NCT05695456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personalized exclusion diet based on CLE
Description: personalized exclusion diet based on CLE
Study NCT05695456 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: personalized exclusion diet based on CLE
Description: personalized exclusion diet based on CLE
Study NCT05695456 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: empiric exclusion diet
Description: exclusion diet with milk or gluten-containing grains
Study NCT05833503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Couple Treatment for Addiction (ICT-A)
Description: Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
Study NCT05833503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment individual as usually offered
Description: Individual-based treatment as usually offer by the specialized centres in addiction.
Study NCT05224492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: 40 mg of Sulforaphane powder once daily.
Study NCT05224492 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05395845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelets rich plasma
Description: local ingection of platelets rich plasma
Study NCT06202950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
Study NCT06202950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
Study NCT04928326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CorWatch
Description: Non-invasive wearable monitor for the assessment of central venous pressure
Study NCT05862025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography evaluation
Description: Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset.
Study NCT05626036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrex Tightrope
Description: High-tensile strength suture syndesmosis repair
Study NCT05864417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Color tone 2.0
Description: Participants will topically apply sunscreen color tone 2.0.
Study NCT05864417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Color tone 3.0
Description: Participants will topically apply sunscreen color tone 3.0.
Study NCT05662098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
Study NCT05626036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes Fibulink
Description: High-tensile strength suture syndesmosis repair
Study NCT05402527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D
Study NCT05402527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein
Study NCT04842318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR for 6 cycles +R for 8 cycles
Description: The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
Study NCT04842318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP for 6 cycles +R for 8 cycles
Description: The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
Study NCT04842318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2 for 6 cycles + R2 maintenance
Description: The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
Study NCT04739202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Ipatasertib
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
Study NCT05402527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin
Study NCT05799040 — intervention group
Intervention type: DEVICE
Intervention: Self-developed pulmonary lobar ventilation detector
Description: The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
Study NCT05799040 — intervention group
Intervention type: DEVICE
Intervention: Chartis detection system
Description: The participants would evaluated by the Chartis detection system.
Study NCT04739202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
Study NCT05038085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise
Description: 36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery.
Study NCT05428358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Description: Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
Study NCT04846400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ssNPA
Description: The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
Study NCT05377749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT
Description: Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
Study NCT06225401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simcapture PRE
Description: Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
Study NCT06225401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simcapture POST
Description: Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
Study NCT06538922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Family Intervention
Description: A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
Study NCT05590728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apramycin (EBL-1003)
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
Study NCT05000593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Intra-articular injection of normal saline
Study NCT05000593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord Blood Mononuclear Cells (UCB-MNCs)
Description: Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
Study NCT04853394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASLIHAT
Description: peer educator intervention
Study NCT04853394 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: TANSIHAT
Description: health education intervention
Study NCT05663541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lower extremity position test
Description: Assessing proprioception of the lower extremity of individuals multiple sclerosis
Study NCT06523894 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Adapted to tumor volume BC SBRT
Study NCT06577597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: Participants will receive single dose of GSK3923868.
Study NCT06577597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single dose of Placebo.
Study NCT06654440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102 for injection
Description: SHR-A2102 for injection
Study NCT05919511 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: This is an observational study
Study NCT05233033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-413
Description: KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.
Study NCT06720857 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium
Description: Identification of a risk stratification model for cardiovascular/hypertensive disorders in the puerperium using a panel of placental biochemical markers (sFlt-1 and PlGF: already used in pregnancy for prediction of preeclampsia), demographic, clinical and laboratory data.
Study NCT06722872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: Laughter therapy, developed by Dr. Madan Kataria in 1995, is a structured exercise program use of laughter and breathing exercises.Laughter therapy sessions begin with warm-up techniques, including clapping, singing, and stretching movements. These are followed by breathing exercises to prepare the lungs for laughter. After the breathing exercises, laughter is simulated using acting techniques. Shortly thereafter, the simulated laughter spreads from person to person through group dynamics, transforming into genuine laughter, which is then followed by a series of laughter exercises. A laughter therapy session may conclude with laughter meditation, during which participants allow natural laughter to flow freely, followed by guided relaxation exercises. To maximize the benefits of laughter's contagious nature, it is recommended that laughter therapy be conducted in groups. Each session varies depending on the target audience, typically lasting around 45 minutes.
Study NCT06723444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning and Memory Training
Description: The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context.~Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions).
Study NCT06723444 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).
Study NCT06726382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine Nasal Spray
Description: 1 x 28 mg dose
Study NCT06726382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: 1 x 5,6 ml p.o.
Study NCT06726382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat 150 MG
Description: 1 x 150 mg tablet
Study NCT06727422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin 66mg + N-acetylcysteine 560mg three times daily
Description: RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
Study NCT06727422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Description: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Study NCT06727422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo three times daily
Study NCT06726369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6204 (SKB535) for Injection
Description: MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study NCT06727279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized food - Plant-Based Meat Analog
Description: Experimental group receives specialized food made of plant-based (soy) meat analog. A portion of standard (animal) meat in a daily ration of the enrolled subjects is substituted by plant-based analog.
Study NCT06727279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard isocalorie diet
Description: Isocalorie (based on resting energy expenditures measurements) diet is provided to subjects of the control group with no modification of the protein and fat content
Study NCT06725992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NS250
Description: Ilaprazole 20mg + Sodium bicarbonate 500mg
Study NCT06725992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-SR
Description: Ilaprazole 10mg
Study NCT06726356 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoalveolar Lavage
Description: Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
Study NCT06726356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage
Description: Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
Study NCT06725628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thy_CLNM_multi_omics
Description: Surgery
Study NCT06656663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Prescribing
Description: SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
Study NCT06656663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Signposting
Description: Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
Study NCT06590961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX-303061
Description: UBX-303061 oral dosage
Study NCT05488067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Oral atorvastatin treatment for ALGS children with xanthoma